Clinical trials
Dyslipidemias trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 10 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Recruiting | 14 |
| Unknown status | 10 |
| Active, not recruiting | 8 |
| Not yet recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Eddingpharm (Zhuhai) Co., Ltd. | 3 |
| Sun Yat-sen University | 3 |
| Wenzhou Medical University | 3 |
| AstraZeneca | 2 |
| Beijing Anzhen Hospital | 2 |
| Central South University | 2 |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2 |
| Shaoguan University | 2 |
| The George Institute for Global Health, China | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyslipidemias | 65 |
| Cardiovascular Diseases | 14 |
| Hypertension | 14 |
| Diabetes Mellitus | 10 |
| Hypercholesterolemia | 9 |
| Hyperlipidemias | 7 |
| Atherosclerosis | 6 |
| Diabetes Mellitus, Type 2 | 6 |
| Hyperlipoproteinemia Type II | 5 |
| Obesity | 5 |
Trials
Showing 51 to 65 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.